Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhIGF-1 Treatment for Primary IGF-1 Deficiency
NCT00125164Phase 3Completed
- Sponsor
- Ipsen
- Start
- Mar 2004
- Primary completion
- Jul 2008
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mecasermin in primary insulin-like growth factor-1 deficiency (PIGFD) (4 arms), sponsored by Ipsen. Primary endpoint: Height Velocity During the First Year at 1 year. Started Mar 2004; status: completed.
02
Drugs
mecasermin
03
Conditions
primary insulin-like growth factor-1 deficiency (PIGFD)
Beyond the preview
Go deeper on NCT00125164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00125164.